DB-289 Immtech International

IDrugs. 2003 Nov;6(11):1086-93.

Abstract

DB-289, an oral diamidoxime prodrug of DB-75 from the University of North Carolina, Georgia State University, Auburn University and Duke University, is being developed by Immtech International as a potential treatment for Pneumocystis carinii pneumonia (PCP), tuberculosis, trypanosomiasis and malaria.

Publication types

  • Review

MeSH terms

  • Animals
  • Antimalarials / adverse effects
  • Antimalarials / chemistry
  • Antimalarials / pharmacokinetics
  • Antimalarials / therapeutic use
  • Antiprotozoal Agents / adverse effects
  • Antiprotozoal Agents / chemistry
  • Antiprotozoal Agents / pharmacokinetics
  • Antiprotozoal Agents / therapeutic use*
  • Antitubercular Agents / adverse effects
  • Antitubercular Agents / chemistry
  • Antitubercular Agents / pharmacokinetics
  • Antitubercular Agents / therapeutic use*
  • Benzamidines / adverse effects
  • Benzamidines / chemistry
  • Benzamidines / metabolism
  • Benzamidines / pharmacokinetics
  • Benzamidines / therapeutic use*
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Humans
  • Prodrugs / adverse effects
  • Prodrugs / chemistry
  • Prodrugs / pharmacokinetics
  • Prodrugs / therapeutic use*
  • Structure-Activity Relationship
  • Trypanocidal Agents / adverse effects
  • Trypanocidal Agents / chemistry
  • Trypanocidal Agents / pharmacokinetics
  • Trypanocidal Agents / therapeutic use

Substances

  • Antimalarials
  • Antiprotozoal Agents
  • Antitubercular Agents
  • Benzamidines
  • Prodrugs
  • Trypanocidal Agents
  • furamidine
  • pafuramidine